Cargando…
Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects
In recent years, antibody-based cancer therapy has emerged as one of the efficient therapeutic strategies, such as immune checkpoint inhibitors (ICIs), angiogenesis inhibitors, antibody-drug conjugates (ADCs), multi-specific antibodies, and chimeric antigen receptor T (CAR-T) cells, among others. To...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131265/ https://www.ncbi.nlm.nih.gov/pubmed/35664074 http://dx.doi.org/10.7150/thno.72594 |
_version_ | 1784713149257089024 |
---|---|
author | Chen, Zhoujiang Kankala, Ranjith Kumar Yang, Zhiyong Li, Wei Xie, Songzhi Li, Hanmei Chen, Ai-Zheng Zou, Liang |
author_facet | Chen, Zhoujiang Kankala, Ranjith Kumar Yang, Zhiyong Li, Wei Xie, Songzhi Li, Hanmei Chen, Ai-Zheng Zou, Liang |
author_sort | Chen, Zhoujiang |
collection | PubMed |
description | In recent years, antibody-based cancer therapy has emerged as one of the efficient therapeutic strategies, such as immune checkpoint inhibitors (ICIs), angiogenesis inhibitors, antibody-drug conjugates (ADCs), multi-specific antibodies, and chimeric antigen receptor T (CAR-T) cells, among others. To date, various drug delivery platforms have been developed to improve the bioavailability, delivery convenience, and reduced toxicity towards increased therapeutic efficacy of antibodies. Herein, we emphasize the clinical manifestations of various antibody-based tumor therapies, highlighting their mechanisms and applications for cancer therapy. Further, based on the problems to be solved in the current clinical application of antibodies, and combined with the advanced drug delivery technologies, we discuss the roles of antibody-based drug delivery systems (DDSs) in cancer therapy, such as enhanced patient compliance and regulating the tumor microenvironment for combined therapy. By expounding the importance of DDSs and discussing the challenges and prospects of their implementation, we suggest that pharmaceutical enterprises and scientists develop appropriate antibody-based delivery platforms. |
format | Online Article Text |
id | pubmed-9131265 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-91312652022-06-04 Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects Chen, Zhoujiang Kankala, Ranjith Kumar Yang, Zhiyong Li, Wei Xie, Songzhi Li, Hanmei Chen, Ai-Zheng Zou, Liang Theranostics Review In recent years, antibody-based cancer therapy has emerged as one of the efficient therapeutic strategies, such as immune checkpoint inhibitors (ICIs), angiogenesis inhibitors, antibody-drug conjugates (ADCs), multi-specific antibodies, and chimeric antigen receptor T (CAR-T) cells, among others. To date, various drug delivery platforms have been developed to improve the bioavailability, delivery convenience, and reduced toxicity towards increased therapeutic efficacy of antibodies. Herein, we emphasize the clinical manifestations of various antibody-based tumor therapies, highlighting their mechanisms and applications for cancer therapy. Further, based on the problems to be solved in the current clinical application of antibodies, and combined with the advanced drug delivery technologies, we discuss the roles of antibody-based drug delivery systems (DDSs) in cancer therapy, such as enhanced patient compliance and regulating the tumor microenvironment for combined therapy. By expounding the importance of DDSs and discussing the challenges and prospects of their implementation, we suggest that pharmaceutical enterprises and scientists develop appropriate antibody-based delivery platforms. Ivyspring International Publisher 2022-05-01 /pmc/articles/PMC9131265/ /pubmed/35664074 http://dx.doi.org/10.7150/thno.72594 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Review Chen, Zhoujiang Kankala, Ranjith Kumar Yang, Zhiyong Li, Wei Xie, Songzhi Li, Hanmei Chen, Ai-Zheng Zou, Liang Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects |
title | Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects |
title_full | Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects |
title_fullStr | Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects |
title_full_unstemmed | Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects |
title_short | Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects |
title_sort | antibody-based drug delivery systems for cancer therapy: mechanisms, challenges, and prospects |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131265/ https://www.ncbi.nlm.nih.gov/pubmed/35664074 http://dx.doi.org/10.7150/thno.72594 |
work_keys_str_mv | AT chenzhoujiang antibodybaseddrugdeliverysystemsforcancertherapymechanismschallengesandprospects AT kankalaranjithkumar antibodybaseddrugdeliverysystemsforcancertherapymechanismschallengesandprospects AT yangzhiyong antibodybaseddrugdeliverysystemsforcancertherapymechanismschallengesandprospects AT liwei antibodybaseddrugdeliverysystemsforcancertherapymechanismschallengesandprospects AT xiesongzhi antibodybaseddrugdeliverysystemsforcancertherapymechanismschallengesandprospects AT lihanmei antibodybaseddrugdeliverysystemsforcancertherapymechanismschallengesandprospects AT chenaizheng antibodybaseddrugdeliverysystemsforcancertherapymechanismschallengesandprospects AT zouliang antibodybaseddrugdeliverysystemsforcancertherapymechanismschallengesandprospects |